A phase 2 clinical trial of the pharmacological chaperone AT2101 for the treatment of Gaucher disease

被引：0
|
作者：
Weinreb, N. [1 ]
Schneider, E. [2 ]
Dinh, Q. [2 ]
Duke, C. [2 ]
Insinga, A. F. [2 ]
Scott, K. [2 ]
Do, H. [2 ]
Wustman, B. [2 ]
Palling, D. [2 ]
Lockhart, D. J. [2 ]
机构：
[1] Res Fdn LSDs Inc, Coral Springs, FL USA
[2] Amicus Therapeut Inc, Cranbury, NJ USA
来源：
JOURNAL OF INHERITED METABOLIC DISEASE | 2008年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
427P
引用
收藏
页码：108 / 108
页数：1
相关论文
共 50 条
  • [1] Pharmacological chaperone therapy for the treatment of Gaucher disease:: AT2101 increases β-glucocerebrosidase levels in cells, mice and healthy human volunteers
    Wustman, B. A.
    Khanna, R.
    Powe, A.
    Pine, C. W.
    Soska, R.
    Pellegrino, L.
    Valenzano, K. J.
    Palling, D. J.
    Marian, A.
    Demnati, R.
    Lockart, D. J.
    Do, H., V
    JOURNAL OF INHERITED METABOLIC DISEASE, 2007, 30 : 120 - 120
  • [2] A Phase2 clinical trial to assess the safety and tolerability of the pharmacological chaperone AT 2101 in treatment-nave adult patients with type I Gaucher disease
    Mehta, Atul
    Hughes, Derralynn
    Schneider, Eugene
    Dinh, Quinn
    MOLECULAR GENETICS AND METABOLISM, 2010, 99 (02) : S27 - S27
  • [3] Pharmacological chaperone therapy for Gaucher disease: Mechanism of action, a survey of responsive mutations and phase I clinical trial results
    Wustman, Brandon
    Pine, Corey
    Ranes, Brian
    Flanagan, John
    Palling, David
    Do, Hung
    Insinga, Frank
    Grabowski, Gregory
    Weinreb, Neal
    Pastores, Gregory
    Fernhoff, Paul
    Kaplan, Paige
    Lockhart, David
    MOLECULAR GENETICS AND METABOLISM, 2008, 93 (02) : S44 - S44
  • [4] A Pharmacological Chaperone for Lysosomal Glucocerebrosidase, Afegostat-tartrate (AT2101), Shows Benefit in a Mouse Model of PD
    Chesselet, Marie-Francoise
    Richter, Franziska
    Fleming, Sheila M.
    Watson, Melanie
    Pellegrino, Lee
    Brignol, Nastry
    Chang, Kate
    Lemesre, Vincent
    Zhu, Chunni
    Mortazavi, Farzad
    Mulligan, Caitlin K.
    Sioshansi, Pedrom
    Hean, Sindalana
    De La Rosa, Krystal
    Khanna, Richie
    Lockhart, David J.
    Wustman, Brandon A.
    Clark, Sean W.
    NEUROTHERAPEUTICS, 2012, 9 (03) : 677 - 678
  • [5] Small Molecular Pharmacological Chaperone for Gaucher Disease
    Li Jing
    Xie Xiaoli
    Wang Jiajia
    Wang Xiaomin
    Li Jing
    Wang Peng
    PROGRESS IN CHEMISTRY, 2014, 26 (05) : 889 - 897
  • [6] Pharmacological chaperone therapy for the treatment of Gaucher disease: Results of phase 1 clinical trials and a clinical ex vivo response study with a survey of blood markers for 53 Gaucher patients
    Weinreb, Neal J.
    Grabowski, G. A.
    Pastores, G. M.
    Fernhoff, P. M.
    Kaplan, P. B.
    Palling, D.
    Pine, C. W.
    Raines, B. E.
    Insinga, F.
    Lockhart, D. J.
    Do, H. V.
    Wustman, B. A.
    BLOOD, 2007, 110 (11) : 709A - 710A
  • [7] Phase 2 clinical trials of the pharmacological chaperone ATI001 for the treatment of Fabry disease
    Germain, D. P.
    Castelli, J.
    Shenker, A.
    Do, H.
    Wustman, B.
    Palling, D.
    Lockhart, D. J.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2008, 31 : 98 - 98
  • [8] Pharmacological chaperone therapy for Gaucher disease: a patent review
    Benito, Juan M.
    Garcia Fernandez, Jose M.
    Ortiz Mellet, Carmen
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (06) : 885 - 903
  • [9] New Insights into the Pharmacological Chaperone Activity of C2-Substituted Glucoimidazoles for the Treatment of Gaucher Disease
    Li, Zhonghua
    Li, Tiehai
    Dai, Shaoxing
    Xie, Xiaoli
    Ma, Xiaofeng
    Zhao, Wei
    Zhang, Weimin
    Li, Jing
    Wang, Peng George
    CHEMBIOCHEM, 2013, 14 (10) : 1239 - 1247
  • [10] Pharmacological treatment of pediatric Gaucher disease
    Gupta, Punita
    Pastores, Gregory
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (12) : 1183 - 1194
12345